Anti-solvent crystallization of celecoxib in the presence of PVP for enhancing the dissolution rate: Comparison of water and supercritical CO2 as two antisolvents

Screening, Synthesis, and Characterization of a More Rapidly Dissolving Celecoxib Crystal Form

The prevalence of poor solubility in active pharmaceutical ingredients (APIs) such as celecoxib (CEL) is a major bottleneck in the pharmaceutical industry, leading to a low concentration gradient, poor passive diffusion, and in vivo failure. This study presents the synthesis and characterization of a new cocrystal of the API CEL. CEL is a nonsteroidal anti-inflammatory drug used for the treatment of osteoarthritis and rheumatoid arthritis. Computational screening was completed for CEL against a large library of generally recognized as safe (GRAS) coformers, based on molecular complementarity and hydrogen bond propensity (HBP). The generated list of 17 coformers with a likelihood for cocrystallization with CEL were experimentally screened using four techniques: liquid-assisted grinding (LAG), solvent evaporation (SE), gas antisolvent crystallization (GAS), and supercritical enhanced atomization (SEA). One new crystalline form was isolated, employing the liquid coformer N-ethylacetamide (NEA). This novel form, celecoxib-di-N-ethylacetamide (CEL·2NEA), was characterized by a variety of different techniques. The crystal structure was determined through single-crystal X-ray diffraction. Both NEA molecules are evolved from the crystal structure at a desolvation temperature of approximately 65 °C. The CEL·2NEA cocrystal exhibited a dissolution rate, with more than a twofold improvement in comparison to as-received CEL after only 15 min.

Genistein microparticles prepared by antisolvent recrystallization with low-speed homogenization process

To create genistein particles, a brand-new antisolvent recrystallization technique was employed. The response surface approach was utilized to optimize the single factor test findings, which were acquired via the preliminary tests. The ideal liquid-to-liquid ratio was 9, the solution concentration was 21 mg/mL, the nozzle diameter was 700 μm, the feed rate was 39.65 mL/min, and the homogenization rate was 1500 rpm. The smallest mean particle size measured was 202.782 nm. SEM was used to study the powder's morphology, while thermal analysis and infrared imaging were used to evaluate its characteristics. The homogeneous antisolvent recrystallization method-prepared GMP has a better dissolving rate and stronger antioxidant activity when compared to genistein powder. The antisolvent recrystallization approach used in this study, which uses low-speed homogenizing instead of conventional grinding and homogenizing, can successfully reduce particle size, improve bioavailability, and use less energy. This topic may thus be made popular because it has real-world applications.

The antisolvent coprecipitation method for enhanced bioavailability of poorly water-soluble drugs

In recent years, poorly water-soluble drug candidates in the drug development pipeline have been a challenging issue for the pharmaceutical industry. Many delivery systems such as nanocrystals, cocrystals, nanoparticles, and amorphous solid dispersions (ASDs) have been developed to overcome these problems. A large number of methods are utilized to realize the above delivery systems. Among all the preparation methods, the antisolvent coprecipitation method is a relatively simple, cost-effective method, offering many advantages over conventional methods. An overview of recent developments for each solubility enhancement approach using the antisolvent coprecipitation method is presented. This current review details a comprehensive overview of the antisolvent coprecipitation process and its properties, as well as the fundamentals for enhancing the solubility and bioavailability of poorly water-soluble drugs by nanotization, polymorph control with polymers and/or surfactants. Furthermore, this review also presents insights into the factors affecting the antisolvent coprecipitation process.